Serum Vitamin D Levels in Relation to Development of Multisystem Inflammatory Syndrome in Pediatric COVID-19

Simple item page
dc.contributor.authorZengin N.
dc.contributor.authorBal A.
dc.contributor.authorGoren T.A.
dc.contributor.authorBayturan S.S.
dc.contributor.authorAlkan F.
dc.contributor.authorAkcali S.
dc.date.accessioned2024-07-22T08:03:42Z
dc.date.available2024-07-22T08:03:42Z
dc.date.issued2022
dc.description.abstractObjective The aim of the study is to evaluate vitamin D (vit D) levels in children with and without development of multisystem inflammatory syndrome in children (MIS-C) after coronavirus disease 2019 (COVID-19) and also between those with severe and moderate MIS-C. Methods This comprises retrospective data of 68 patients including 34 patients with MIS-C and admitted into the pediatric intensive care unit (MIS-C group) and 34 patients without MIS-C (non-MIS-C group) were analyzed for their presenting characteristics, serum vit D levels, ventilatory needs, and prognostic scores. Results Vit D levels were significantly lower in patients with versus without MIS-C [9 (2-18) vs. 19 (10-43) ng/mL, p <0.001], and also in patients with severe versus moderate MIS-C [7.5 (2-17) vs. 9 (5-18) ng/mL, p = 0.024]. Vit D deficiency (levels <12 ng/mL) was more common in the MIS-C versus non-MIS-C group (79.4 vs. 11.8%, p <0.001) and in severe versus moderate MIS-C (92.9 vs. 70.0%, p <0.001). The severe versus moderate MIS-C was associated with significantly higher levels of procalcitonin [7.6 (0.9-82) vs. 1.7 (0.2-42) ng/mL, p = 0.030] and troponin [211 (4.8-4,545) vs. 14.2 (2.4-3,065) ng/L, p = 0.008] and higher likelihood of reduced ejection fraction (75.0 vs. 15.4%, p = 0.004). Conclusion Our findings indicate the higher prevalence of vit D deficiency in pediatric COVID-19 patients with versus without MIS-C, as well as in those with severe versus moderate MIS-C. Higher troponin and procalcitonin levels and dyspnea at presentation seem also to be risk factors for severe MIS-C, more pronounced cardiac dysfunction, and poorer prognosis. © 2022 Georg Thieme Verlag. All rights reserved.
dc.identifier.DOI-ID10.1055/s-0042-1756713
dc.identifier.issn13057707
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12393
dc.language.isoEnglish
dc.publisherGeorg Thieme Verlag
dc.rightsAll Open Access; Bronze Open Access
dc.subjectacetylsalicylic acid
dc.subjectceftriaxone
dc.subjectepinephrine
dc.subjectimmunoglobulin
dc.subjectlow molecular weight heparin
dc.subjectmethylprednisolone
dc.subjectmilrinone
dc.subjectprocalcitonin
dc.subjecttroponin
dc.subjectvancomycin
dc.subjectvitamin D
dc.subjectArticle
dc.subjectartificial ventilation
dc.subjectchild
dc.subjectclinical feature
dc.subjectcontrolled study
dc.subjectcoronavirus disease 2019
dc.subjectdisease course
dc.subjectdisease severity
dc.subjectfemale
dc.subjectheart ejection fraction
dc.subjecthospital admission
dc.subjecthuman
dc.subjecthuman tissue
dc.subjecthypotension
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpediatric intensive care unit
dc.subjectpediatric multisystem inflammatory syndrome
dc.subjectpediatric patient
dc.subjectprevalence
dc.subjectprognosis
dc.subjectprotein expression
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjectvitamin blood level
dc.titleSerum Vitamin D Levels in Relation to Development of Multisystem Inflammatory Syndrome in Pediatric COVID-19
dc.typeArticle

Files

Collections

Scopus Koleksiyonu